WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Download the WorkBoat Show App! Plan your schedule, explore exhibitors, and access event details anytime. Get the app › Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.3878 -0.0091 (-2.29%)
Streaming Delayed Price Updated: 2:03 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 Next >
FibroBiologics to Present at Bio-Europe 2025
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the 2025 ThinkEquity Conference
From FibroBiologics, Inc.
Via GlobeNewswire
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
Pilot studies underway to advance IND-enabling preclinical development 
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology 
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
From FibroBiologics, Inc.
Via GlobeNewswire
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
From FibroBiologics, Inc.
Via GlobeNewswire
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2025
From FibroBiologics, Inc.
Via GlobeNewswire
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third... 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Presenting at the ThymUS 2025 Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces 2025 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.